Vascular Endothelial Growth Factor (e.g., Vegf-a, Vegf-b, Etc.) Or Derivative Patents (Class 514/8.1)
  • Patent number: 10081667
    Abstract: A composition including an elastin-like polypeptide (ELP) coupled to a therapeutic agent is provided. The ELP comprises at least about 5 repeats of the amino acid sequence VPGXG. Further provided is a method of using the composition for therapeutic agent delivery during pregnancy to reduce the amount of the therapeutic agent crossing a placenta in a pregnant subject. The method includes administering to the pregnant subject an effective amount of the composition comprising the ELP coupled to the therapeutic agent.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: September 25, 2018
    Assignee: University of Mississippi Medical Center
    Inventors: Gene L. Bidwell, III, Eric M. George
  • Patent number: 10039831
    Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: August 7, 2018
    Assignees: Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.
    Inventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
  • Patent number: 9119974
    Abstract: The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising exosomes and cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of making and using such compositions and kits comprising the skin cream therein.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: September 1, 2015
    Inventor: Ahmed H. Al-Qahtani
  • Publication number: 20150132354
    Abstract: The invention provides a novel composite bone graft system utilizing a porous collagen scaffold having a matrix impregnated with calcium phosphate particles and more than one bioactive agent, one of which is conjugated to the matrix. The graft system exhibits increased mechanical strength and osteogenic properties by providing sites for tissue attachment and propagation. The bioactive agents are delivered to the scaffold via different mechanisms to enable sequential and sustained release of the bioactive agents over time.
    Type: Application
    Filed: August 5, 2014
    Publication date: May 14, 2015
    Applicant: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Ryan K. Roeder, Matthew J. Meagher, Robert J. Kane
  • Publication number: 20150126446
    Abstract: The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 7, 2015
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Donald P. Bottaro, Fabiola Cecchi
  • Patent number: 9012399
    Abstract: The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purpose of promoting angiogenesis in target tissues.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: April 21, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Lan Cao, David J. Mooney
  • Publication number: 20150093375
    Abstract: The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders.
    Type: Application
    Filed: April 25, 2014
    Publication date: April 2, 2015
    Applicant: GENENTECH, INC.
    Inventors: Harald J. JUNGE, Weilan YE
  • Publication number: 20150086599
    Abstract: Provided are systems for controlled release of proteins from decomposable thin films constructed by layer-by-layer deposition. Such films generally comprise alternating layers of polymers and proteins, and may further comprise additional layers of polyions. In some embodiments, decomposable thin films and methods of using such films allow proteins to be released over an extended period of time and/or retention of as much as 100% of function of released protein.
    Type: Application
    Filed: October 10, 2014
    Publication date: March 26, 2015
    Inventors: Paula T. Hammond, Mara L. Macdonald
  • Publication number: 20150080299
    Abstract: Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7.
    Type: Application
    Filed: April 11, 2014
    Publication date: March 19, 2015
    Applicant: Stryker Corporation
    Inventor: Niles Ron
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Publication number: 20150056161
    Abstract: This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject a composition comprising an amount of a human stromal derived factor-1 and an amount of a human granulocyte-colony stimulating factor, the composition being administered in an amount effective to cause proliferation of cardiomyocytes within the subject's heart so as to thereby treat the disorder. This invention also provides a method of treating a subject suffering from a disorder of a tissue involving loss and/or apoptosis of cells of the tissue which comprises administering to the subject a composition comprising an amount of an agent which induces phosphorylation and/or activation of protein kinase B, or an agent which induces phosphorylation and/or activation of an extracellular signal-regulated protein kinase, or an agent which induces activation of CXCR4.
    Type: Application
    Filed: March 4, 2014
    Publication date: February 26, 2015
    Applicant: The Trustees of Columbia University in the City of New York
    Inventor: Silviu Itescu
  • Patent number: 8962555
    Abstract: The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: February 24, 2015
    Assignees: Dompe S.p.A., Geymonat S.p.A.
    Inventors: Gaetano D'Anniballe, Franck Martin, Giuseppe Salvia
  • Publication number: 20150050331
    Abstract: The present invention is directed to a method of making a stable composition comprising growth factors, which may include platelet derived growth factors and transforming growth factors. The method comprises providing human umbilical cord blood plasma containing platelets, but substantially free of whole blood cells, and lysing the platelets to extrude growth factors into the plasma. The plasma may be obtained from multiple donors and pooled to form a homologous plasma mixture. In another embodiment, the growth factors are encapsulated in a liposome formed by a lipid bilayer, wherein the resulting composition remains stable and viable for at least 30 months. The present invention is also directed to the composition produced by the methods of the present invention and the process of applying the composition to a skin defect or wound.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 19, 2015
    Applicant: NOVO SOLUTIONS MD, LLC
    Inventor: ALVIN DAVID NEEDLEMAN
  • Publication number: 20150051147
    Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).
    Type: Application
    Filed: August 12, 2014
    Publication date: February 19, 2015
    Applicant: STEMNION, INC.
    Inventors: George L. Sing, Randall G. Rupp, David L Steed
  • Publication number: 20150050332
    Abstract: In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can be genetic material encoding the expression of specific proteins such as transcription factors, the expression of which can initiate the reprogramming of the cells. In other embodiments, the effector molecules can induce angiogenesis. In other embodiments, the effector molecules are tumor antigens.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 19, 2015
    Inventor: Shai Yehoshua Schubert
  • Publication number: 20150044166
    Abstract: Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (EIPH) and nasopharyngeal cicatrix (NC) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and an effective amount of each of one or more stem cell derived factors. Exemplary stem cell derived factors include, but are not limited to, growth factors, chemokines, and cytokines. The mammal may be a horse, dog, camel, or Homo sapiens.
    Type: Application
    Filed: August 7, 2014
    Publication date: February 12, 2015
    Inventor: Michael Riddle, JR.
  • Publication number: 20150025007
    Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
    Type: Application
    Filed: August 1, 2014
    Publication date: January 22, 2015
    Inventors: Charlotte A. Emig, Catherine J. Trumpower, George L. Sing
  • Publication number: 20150023911
    Abstract: The present invention relates to an in vitro or ex vivo method of preparing a cell-free composition, said method comprising or consisting of (a) subjecting cells to stress; and (b) collecting factors produced, preferably secreted by said cells when subjected to said stress, thereby obtaining said cell-free composition; wherein said cells are comprised in or form at least one first carrier and said collecting is effected by means of at least one second carrier which second carrier(s) is/are cell-free and concomitantly present with and spatially distinct from said first carrier; and said collecting is effected using a device comprising or consisting of (i) said first carrier(s) which first carrier(s) comprise(s) said cells or is/are suitable to hold said cells; (ii) said second carrier(s) which is cell-free; and (iii) means of subjecting said cells in said first carrier to stress; wherein first carrier(s) and second carrier(s) are positioned such that factors secreted by said cells when subjected to stress are
    Type: Application
    Filed: January 31, 2013
    Publication date: January 22, 2015
    Applicant: Technische Universitaet Muenchen-Klimikum Rechts Der Isar
    Inventors: Arndt Schilling, Ektoras Hadjipanayi, Hans-Guenther Machens
  • Publication number: 20150024051
    Abstract: A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be released by the microspheres at different times.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 22, 2015
    Inventors: Michael Gerard Keeney, Fan Yang, Stuart Barry Goodman
  • Patent number: 8936804
    Abstract: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: January 20, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Sheldon Suton Lin, David Naisby Paglia, James Patrick O'Connor, Eric Breitbart, Joseph Benevenia
  • Patent number: 8936805
    Abstract: A structure of, and a method of producing, a biocompatible structure for bone and tissue regeneration are disclosed. The method includes dissolving a polyurethane polymer in methanol, adding hydroxyapatite (HAP) nanoparticles to form a uniformly distributed mixture, applying the mixture to a polytetrafluoroethylene (PTFE) surface to form a polymer film, cutting the polymer film into strips, stacking the strips with layers of bone particles disposed therebetween, coating the stacked strips and layers by the mixture and allowing it to dry, adding bone particles to the coating, and plasma treating the structure to form the biocompatible structure. A weight percentage of the HAP nanoparticles to the polymer is about 5-50% such that a resorption rate of the biocompatible structure substantially matches a rate of tissue generation in the biocompatible structure.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: January 20, 2015
    Assignee: Board of Trustees of the University of Arkansas
    Inventor: Alexandru S. Biris
  • Publication number: 20150018750
    Abstract: As the percentage of senior citizens increases at the present time, the purpose of the present invention is to provide a cosmetic which can maintain the skin in a healthy state by preventing damage to the skin that accompanies aging, more specifically, discoloration and wrinkling, is very safe, does not pose ethical problems, and can be supplied in a sufficient amount. The present invention provides a cosmetic that comprises as the main component a powder of the supernatant produced by culturing the bone marrow or dental pulp stem cells of a nonhuman mammal. Moreover, provided is a method for ion introduction for protein by which the cosmetic is introduced by ion introduction.
    Type: Application
    Filed: August 8, 2014
    Publication date: January 15, 2015
    Applicant: JAPANIC CORPORATION
    Inventors: Minoru Ueda, Yasuhiro Yamashita
  • Patent number: 8927232
    Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: January 6, 2015
    Assignee: Korea Advanced Institute of Science and Technology (KAIST)
    Inventors: Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
  • Publication number: 20150005234
    Abstract: Provided herein are soft tissue implants, methods of making, use, and administration thereof. The soft tissue implants can be prepared by harvesting cells or tissue from a donor and selectively lysing the cells or tissue to obtain the intracellular content. Also provided herein are delivery devices for delivering the soft tissue implants described herein and kits that include the soft tissue implants described herein.
    Type: Application
    Filed: July 1, 2014
    Publication date: January 1, 2015
    Inventor: Amit Prakash Govil
  • Publication number: 20150005235
    Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
    Type: Application
    Filed: September 3, 2014
    Publication date: January 1, 2015
    Inventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
  • Patent number: 8921316
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: December 30, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • Publication number: 20140377330
    Abstract: The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Inventors: Carsten Werner, Uwe Freudenberg, Dorit Meinhold, Marie-Francoise Gouzy, Petra Welzel
  • Publication number: 20140379094
    Abstract: The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation.
    Type: Application
    Filed: May 16, 2014
    Publication date: December 25, 2014
    Applicants: TRUSTEES OF TUFTS COLLEGE, UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE AFM, UNIVERSITY OF ILLINOIS AT CHICAGO
    Inventors: David L. Kaplan, Jia Huang, Cheryl Wong Po Foo, Rajesh Naik, Anne George
  • Publication number: 20140377276
    Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 25, 2014
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kyung Jin Kim
  • Publication number: 20140370094
    Abstract: The inventions provided herein relate to silk-based scaffolds and methods of producing the same, which can be used for a range of tissue engineering applications. The fabrication methods described herein provide a versatile platform to incorporate hollow conduits (e.g., for nutrient/oxygen delivery) through three-dimensional silk-based scaffolds that have tunable bulk properties (e.g., but not limited to, porosity, mechanical, degradation rate) and allow endothelialization and/or cell compartmentalization, for engineering a variety of complex tissue equivalents.
    Type: Application
    Filed: November 8, 2012
    Publication date: December 18, 2014
    Inventors: Lindsay Wray, Jelena Rnjak-Kovacina, David L. Kaplan
  • Patent number: 8906648
    Abstract: A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: December 9, 2014
    Assignee: Genentech, Inc.
    Inventors: Michelle D. Butler, Jeffrey L. Cleland, David W. Kahn, Shelly Pizarro, Charles H. Schmelzer, Marjorie E. Winkler
  • Publication number: 20140356286
    Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.
    Type: Application
    Filed: April 21, 2014
    Publication date: December 4, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
  • Publication number: 20140349929
    Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Application
    Filed: March 28, 2014
    Publication date: November 27, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
  • Publication number: 20140341814
    Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.
    Type: Application
    Filed: April 22, 2014
    Publication date: November 20, 2014
    Inventors: Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
  • Patent number: 8889620
    Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: November 18, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Michael Klagsbrun, Shay Soker
  • Publication number: 20140335145
    Abstract: The invention provides products of manufacture, e.g., biomaterials and implants, for cartilage maintenance and/or formation in-vivo, in-vitro, and ex-vivo, using nanotechnology, e.g., using nanotube, nanowire, nanopillar and/or nanodepots configured on surface structures of the products of manufacture.
    Type: Application
    Filed: July 27, 2014
    Publication date: November 13, 2014
    Inventors: Sungho JIN, Seunghan OH, Karla BRAMMER
  • Patent number: 8883724
    Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: November 11, 2014
    Assignee: Centro de Ingenieria Genética y Biotecnologia
    Inventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
  • Patent number: 8883184
    Abstract: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: November 11, 2014
    Assignee: Pioneer Surgical Technology, Inc.
    Inventors: Ronald Stewart Hill, Richard Chris Klann, Francis V. Lamberti
  • Patent number: 8883738
    Abstract: The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 11, 2014
    Assignee: Karisruher Insitut für Technologie
    Inventors: Alexandra Matzke, Helmut Ponta, Véronique Orian-Rousseau, Martina Tremmel
  • Publication number: 20140322292
    Abstract: Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic agents or compositions thereof to patients in need of such treatment are also disclosed.
    Type: Application
    Filed: November 29, 2012
    Publication date: October 30, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Sheldon S. Lin, David N. Paglia, James P. O'Connor, Joseph Benevenia, Aaron Wey, Sangeeta Subramanian, John D. Koerner
  • Publication number: 20140315804
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 23, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Publication number: 20140315803
    Abstract: A method for promoting hair growth in a human in need of promoting hair growth. The method includes preparing a composition comprising a therapeutically effective amount of at least three of: a Bone Morphogenetic Protein, Transforming Growth Factor Beta, Platelet Derived Growth Factor, Insulin-like Growth Factor, Basic Fibroblastic Growth Factor and Vascular Endothelial Growth Factor; and administering the composition to the human.
    Type: Application
    Filed: April 17, 2013
    Publication date: October 23, 2014
    Inventor: Mark Laney
  • Publication number: 20140308264
    Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.
    Type: Application
    Filed: June 23, 2014
    Publication date: October 16, 2014
    Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
  • Patent number: 8859706
    Abstract: The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: October 14, 2014
    Assignee: Zetascience GmbH
    Inventors: Carsten Werner, Uwe Freudenberg, Dorit Meinhold, Marie-Francoise Gouzy, Petra Welzel
  • Publication number: 20140302111
    Abstract: Provided is a method for regenerating dental tissue, which can include contacting a scaffold containing Wnt3a and BMP-7, and optionally VEGF, bFGF, or NGF, with a dental tissue so as to promote odontoblastic differentiation of a progenitor cell, promote progenitor cell migration into the dental tissue, or regenerate the dental tissue. Also provided is a composition for regeneration of dental tissue, which can include a scaffold and Wnt3a and BMP-7, and optionally VEGF, bFGF, or NGF.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 9, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Jeremy J. Mao, Ying Zheng, Guoming Sun, Songlin Wang
  • Publication number: 20140294960
    Abstract: Implantable modular hydrogels to aid in salivary gland restoration and associated methods are provided. In one embodiment, the present disclosure provides for a hydrogel network comprising: a hyaluronic acid macromer crosslinked with a multiblock copolymer.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Robert L. Witt, Xinqiao Jia, Swati Pradham Bhatt, Mary C. Farach-Carson, Daniel A. Harrington
  • Patent number: 8840883
    Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. Addition of a non-protein-type metal chelator provided further improvement in the action of the bio-functional activity of T3. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: September 23, 2014
    Assignee: Naidu LP
    Inventors: A. Satyanarayan Naidu, A. G. Sreus Naidu, A. G. Tezus Naidu
  • Publication number: 20140271779
    Abstract: Synthetic, bioactive ultra-porous bone graft materials having an engineered porosity, and implants formed from such materials are provided. In particular, these implants comprise bioactive glass and incorporate allograft material for osteoinduction. The implants are suitable for bone tissue regeneration and/or repair.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Applicant: PROSIDYAN, INC.
    Inventors: Charanpreet S. BAGGA, Steve B. JUNG, Hyun W. BAE
  • Publication number: 20140271589
    Abstract: Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: BIOMET BIOLOGICS, LLC
    Inventors: Andrea MATUSKA, Krista O'SHAUGHNESSEY, Jennifer E. WOODELL-MAY
  • Publication number: 20140256630
    Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.
    Type: Application
    Filed: January 7, 2014
    Publication date: September 11, 2014
    Applicant: Indi Molecular, Inc.
    Inventors: Suresh Mark PITRAM, Heather Dawn AGNEW, Tsun Yin LAI, Rosemary Dyane ROHDE, Paul Edward Kearney, Scott LAW, Kenneth Charles FANG